Research Article

Targeted Delivery of Paclitaxel in Liver Cancer Using Hyaluronic Acid Functionalized Mesoporous Hollow Alumina Nanoparticles

Figure 2

The XRD (a) and DSC (b) characterization of PAC, HMHA, PM, PAC-MHA, and PAC-HMHA. PAC, paclitaxel; HMHA, hyaluronic acid functionalized mesoporous hollow alumina nanoparticles; PM, the physical mixture of the drug and HMHA; PAC-MHA, paclitaxel-mesoporous hollow alumina nanoparticles; PAC-HMHA, paclitaxel-hyaluronic acid functionalized mesoporous hollow alumina nanoparticles.

(a)
(b)